Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

NCT05560607 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
NAFLD
Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
NASH

Interventions

DRUG: AZD7503 Intervention

Sponsor

AstraZeneca